The treatment showed strong and lasting benefits in 580 adults with moderate to severe ulcerative colitis in the maintenance trial.
Both the 25 mg and 50 mg doses achieved the main goal of clinical remission at week 44.
Abivax said it remains on track to file for FDA approval of obefazimod in ulcerative colitis by late 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.